Liberty Wealth Management LLC Cuts Holdings in Hims & Hers Health, Inc. $HIMS

Liberty Wealth Management LLC lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 14.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,629 shares of the company’s stock after selling 1,113 shares during the period. Liberty Wealth Management LLC’s holdings in Hims & Hers Health were worth $330,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northern Trust Corp raised its position in shares of Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd grew its stake in Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after purchasing an additional 700,100 shares during the last quarter. Nuveen LLC bought a new position in Hims & Hers Health in the first quarter worth about $58,403,000. BIT Capital GmbH raised its holdings in Hims & Hers Health by 7.4% in the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after purchasing an additional 112,949 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after buying an additional 15,339 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. KeyCorp started coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $38.92.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $54.38, for a total transaction of $143,400.06. Following the completion of the sale, the insider directly owned 161,130 shares in the company, valued at approximately $8,762,249.40. The trade was a 1.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the sale, the insider owned 169,940 shares in the company, valued at $8,581,970. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,429,634 shares of company stock worth $74,097,471. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Trading Down 0.8%

NYSE:HIMS opened at $48.40 on Tuesday. The company has a market capitalization of $10.94 billion, a P/E ratio of 60.50, a PEG ratio of 3.38 and a beta of 2.25. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12 month low of $18.33 and a 12 month high of $72.98. The firm has a fifty day simple moving average of $51.20 and a 200-day simple moving average of $49.94.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the business earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.